trending Market Intelligence /marketintelligence/en/news-insights/trending/bv7jr-rn0a8nyofuntn2ta2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Motif Bio delays US regulatory filing of antibiotic

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Motif Bio delays US regulatory filing of antibiotic

Motif Bio PLC said that it would be delaying the submission of a new drug application with the U.S. Food and Drug Administration for the approval of its antibiotic iclaprim.

The New-York-based biopharmaceutical company now plans to submit an application for iclaprim to treat acute bacterial skin and skin structure infections during the second quarter of 2018.

Motif Bio, which had planned to submit the application this quarter, said it was taking additional time to strengthen its filing.